New Therapeutic Approaches for Advanced Gastrointestinal Stromal Tumors

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2009 Mar 3

PMID 19248977

Citations 2

Authors

Neeta Somaiah

Margaret von Mehren

Affiliations

Soon will be listed here.

Abstract

The management of advanced gastrointestinal stromal tumor is increasingly complex because of imatinib refractory disease. Primary resistance to imatinib is uncommon, and most patients progress after development of additional genetic changes. This article reviews management strategies including surgical approaches, local modalities for progressive liver metastases, as well as novel therapeutic agents.

Citing Articles

The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor.

Liu P, Tan F, Liu H, Li B, Lei T, Zhao X Onco Targets Ther. 2020; 13:2433-2447.

PMID: 32273716 PMC: 7102917. DOI: 10.2147/OTT.S241331.

Optimal use of targeted agents for advanced gastrointestinal stromal tumours.

Reichardt P Oncology. 2010; 78(2):130-40.

PMID: 20389135 PMC: 7068782. DOI: 10.1159/000312655.

References

Verweij J, Casali P, Zalcberg J, Lecesne A, Reichardt P, Blay J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-34. DOI: 10.1016/S0140-6736(04)17098-0. View

Agaram N, LaQuaglia M, Ustun B, Guo T, Wong G, Socci N . Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008; 14(10):3204-15. PMC: 3805121. DOI: 10.1158/1078-0432.CCR-07-1984. View

Guo T, Agaram N, Wong G, Hom G, DAdamo D, Maki R . Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007; 13(16):4874-81. DOI: 10.1158/1078-0432.CCR-07-0484. View

Miettinen M, Sobin L, Sarlomo-Rikala M . Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000; 13(10):1134-42. DOI: 10.1038/modpathol.3880210. View

Demetri G, van Oosterom A, Garrett C, Blackstein M, Shah M, Verweij J . Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544):1329-38. DOI: 10.1016/S0140-6736(06)69446-4. View

Fumo G, Akin C, Metcalfe D, Neckers L . 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood. 2003; 103(3):1078-84. DOI: 10.1182/blood-2003-07-2477. View

Zalcberg J, Verweij J, Casali P, Cesne A, Reichardt P, Blay J . Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005; 41(12):1751-7. DOI: 10.1016/j.ejca.2005.04.034. View

Heinrich M, Corless C, Duensing A, McGreevey L, Chen C, Joseph N . PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607):708-10. DOI: 10.1126/science.1079666. View

Joensuu H, de Braud F, Coco P, De Pas T, Putzu C, Spreafico C . Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol. 2007; 19(1):173-7. DOI: 10.1093/annonc/mdm419. View

10.

Santini V, Gozzini A, Ferrari G . Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 2007; 8(4):383-93. DOI: 10.2174/138920007780655397. View

11.

Xu W, Neckers L . Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res. 2007; 13(6):1625-9. DOI: 10.1158/1078-0432.CCR-06-2966. View

12.

Wang L, Vargas H, French S . Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch Pathol Lab Med. 2000; 124(10):1471-5. DOI: 10.5858/2000-124-1471-COOGST. View

13.

Lasota J, Corless C, Heinrich M, Debiec-Rychter M, Sciot R, Wardelmann E . Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol. 2008; 21(4):476-84. DOI: 10.1038/modpathol.2008.2. View

14.

Kobayashi K, Gupta S, Trent J, Vauthey J, Krishnamurthy S, Ensor J . Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer. 2006; 107(12):2833-41. DOI: 10.1002/cncr.22336. View

15.

Blay J, Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C . Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25(9):1107-13. DOI: 10.1200/JCO.2006.09.0183. View

16.

Roberts K, Odell A, Byrnes E, Baleato R, Griffith R, Lyons A . Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther. 2007; 6(3):1159-66. DOI: 10.1158/1535-7163.MCT-06-0641. View

17.

Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm S . Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007; 13(11):3363-9. DOI: 10.1158/1078-0432.CCR-06-2667. View

18.

Debiec-Rychter M, Sciot R, Cesne A, Schlemmer M, Hohenberger P, van Oosterom A . KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42(8):1093-103. DOI: 10.1016/j.ejca.2006.01.030. View

19.

Bonvalot S, Eldweny H, Le Pechoux C, Vanel D, Terrier P, Cavalcanti A . Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006; 13(12):1596-603. DOI: 10.1245/s10434-006-9047-3. View

20.

Miettinen M, Lasota J . Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438(1):1-12. DOI: 10.1007/s004280000338. View